MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 527416 | Name: Bromotetrandrine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bromotetrandrine, also known as BrTet and W-198, is an P-glycoprotein inhibitor. P-gp inhibitors were developed and coadministered with chemotherapeutic drugs to overcome the effect of efflux pumps thus enhancing the chemosensitivity of therapeutics. The pharmacokinetics parameters of bromotetrandrine indicated that the compound was rapidly distributed and accumulated in the tissues, and slowly cleared from plasma, which supported the use of BrTet for a once or twice dosing per chemotherapy cycle.

Chemical Structure

Bromotetrandrine
Bromotetrandrine
CAS#62067-29-2

Theoretical Analysis

MedKoo Cat#: 527416

Name: Bromotetrandrine

CAS#: 62067-29-2

Chemical Formula: C38H41BrN2O6

Exact Mass: 700.2148

Molecular Weight: 701.66

Elemental Analysis: C, 65.05; H, 5.89; Br, 11.39; N, 3.99; O, 13.68

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Bromotetrandrine; BrTet; W-198; W 198; W198; 5-Bromotetrandrine
IUPAC/Chemical Name
(11S,31S)-35-bromo-16,36,37,54-tetramethoxy-12,32-dimethyl-11,12,13,14,31,32,33,34-octahydro-2,6-dioxa-1(7,1),3(8,1)-diisoquinolina-5(1,3),7(1,4)-dibenzenacyclooctaphane
InChi Key
ANJMFZGRGHQXMA-VMPREFPWSA-N
InChi Code
InChI=1S/C38H41BrN2O6/c1-40-15-13-24-20-31(43-4)33-21-27(24)28(40)17-22-7-10-25(11-8-22)46-32-19-23(9-12-30(32)42-3)18-29-34-26(14-16-41(29)2)35(39)37(44-5)38(45-6)36(34)47-33/h7-12,19-21,28-29H,13-18H2,1-6H3/t28-,29-/m0/s1
SMILES Code
CN([C@@]1([H])CC2=CC=C(OC3=C(OC)C=CC(C[C@]4([H])N(C)CCC5=C4C6=C(OC)C(OC)=C5Br)=C3)C=C2)CCC7=C1C=C(O6)C(OC)=C7
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 701.66 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zheng L, Qing YP, Xu N, Yu Q, Wang Y, Wang FP, Li ZY. Pharmacokinetics and safety of bromotetrandrine (BrTet, W198) after single-dose intravenous administration in healthy Chinese volunteers. J Clin Pharm Ther. 2010 Feb;35(1):113-9. doi: 10.1111/j.1365-2710.2009.01075.x. PubMed PMID: 20175820. 2: Song N, Zhang S, Li Q, Liu C. Liquid chromatographic/mass spectrometry assay of bromotetrandrine in rat plasma and its application to pharmacokinetic study. Biomed Chromatogr. 2009 Jun;23(6):623-9. doi: 10.1002/bmc.1163. PubMed PMID: 19277964. 3: Cao X, Luo J, Gong T, Zhang ZR, Sun X, Fu Y. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo. Mol Pharm. 2015 Jan 5;12(1):274-86. doi: 10.1021/mp500637b. PubMed PMID: 25469833. 4: Luo JW, Zhang T, Zhang Q, Cao X, Zeng X, Fu Y, Zhang ZR, Gong T. A novel injectable phospholipid gel co-loaded with doxorubicin and bromotetrandrine for resistant breast cancer treatment by intratumoral injection. Colloids Surf B Biointerfaces. 2016 Apr 1;140:538-47. doi: 10.1016/j.colsurfb.2015.11.029. PubMed PMID: 26628333. 5: Zhang W, Chen BA, Jin JF, He YJ, Niu YQ. Involvement of c-Jun N-terminal kinase in reversal of multidrug resistance of human leukemia cells in hypoxia by 5-bromotetrandrine. Leuk Lymphoma. 2013 Nov;54(11):2506-16. doi: 10.3109/10428194.2013.776681. Retraction in: Leuk Lymphoma. 2016 May;57(5):1244. PubMed PMID: 23418897. 6: Wu YN, Chen BA, Cheng J, Gao F, Xu WL, Ding JH, Gao C, Sun XC, Li GH, Chen WJ, Liu LJ, Li XM, Wang XM. Reversal of multidrug resistance in xenograft nude-mice by magnetic Fe(3)O(4) nanoparticles combined with daunorubicin and 5-bromotetrandrine. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Feb;17(1):60-4. PubMed PMID: 19236748. 7: Cheng J, Dai JY, Chen BA, Cai XH, Wang S, Gao F. Mechanisms of tetrandrine and 5-bromotetrandrine in reversing multidrug resistance may relate to down-regulation of multidrug resistance associated protein 7 expression. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Jun;20(3):558-63. PubMed PMID: 22739155. 8: Cheng J, Wu W, Chen BA, Gao F, Xu W, Gao C, Ding J, Sun Y, Song H, Bao W, Sun X, Xu C, Chen W, Chen N, Liu L, Xia G, Li X, Wang X. Effect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cells. Int J Nanomedicine. 2009;4:209-16. PubMed PMID: 19918367; PubMed Central PMCID: PMC2775691. 9: Cai XH, Chen BA, Cheng J, Wang J, Ding JH, Bao W, Zhong YJ, Gao F, Xu WL, Shen HL, Wei HL, Chen J. [Effects of 5-bromotetrandrine and daunorubicin on apoptosis and expression of survivin in K562/A02 cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Feb;19(1):24-7. Chinese. PubMed PMID: 21362215. 10: Chen BA, Shan XY, Chen J, Xia GH, Xu WL, Schmit M. Effects of imatinib and 5-bromotetrandrine on the reversal of multidrug resistance of the K562/A02 cell line. Chin J Cancer. 2010 Jun;29(6):591-5. PubMed PMID: 20507731. 11: Liu XD, Sun H, Liu GT. 5-Bromotetrandrine enhances the sensitivity of doxorubicin-induced apoptosis in intrinsic resistant human hepatic cancer Bel7402 cells. Cancer Lett. 2010 Jun 1;292(1):24-31. doi: 10.1016/j.canlet.2009.11.001. PubMed PMID: 19962232. 12: Chen LM, Liang YJ, Zhang X, Su XD, Dai CL, Wang FP, Yan YY, Tao LY, Fu LW. Reversal of P-gp-mediated multidrug resistance by Bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue. Anticancer Res. 2009 Nov;29(11):4597-604. PubMed PMID: 20032409. 13: Cheng J, Wang JQ, Chen BA, Gao F, Xu WL, Shen HL, Ding JH, Gao C, Sun YY, Wang J, Zhao G, Song HH, Bao W, Sun Q, Dai YY, Sun XC, Cheng HY, Deng YX, Li GH, Chen NN, Liu LJ, Wang XM. MDR reversal activity of bromotetrandrine in vitro and in vivo. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Oct;17(5):1183-91. PubMed PMID: 19840447. 14: Wei Zhang, Bao-an Chen, Jun-fei Jin, You-ji He, and Yi-qi Niu, Involvement of c-Jun N-terminal kinase in reversal of multidrug resistance of human leukemia cells in hypoxia by 5-bromotetrandrine. November 2013;54(11):2506-2516. http://dx.doi.org/10.3109/10428194.2013.776681. Leuk Lymphoma. 2016 May;57(5):1244. doi: 10.3109/10428194.2016.1158967. PubMed PMID: 26943699. 15: Shen MF, Chen BA, Cheng J, Gao F, Xu WL, Ding JH, Gao C, Sun XC, Li GH, Chen WJ, Liu LJ, Li XM, Wang XM. Effects of magnetic nanoparticle of fe(3)o(4) and 5-bromotetrandrine on apoptosis of K562/A02 leukemic cells induced by daunorubicin. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Feb;17(1):54-9. PubMed PMID: 19236747. 16: Chen B, Cheng J, Wu Y, Gao F, Xu W, Shen H, Ding J, Gao C, Sun Q, Sun X, Cheng H, Li G, Chen W, Chen N, Liu L, Li X, Wang X. Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice. Int J Nanomedicine. 2009;4:73-8. PubMed PMID: 19421372; PubMed Central PMCID: PMC2720736. 17: Wang JQ, Chen BA, Cheng J, Xu WL, Sun XC. [Comparison of reversal effects of 5-bromotetrandrine and tetrandrine on P-glycoprotein-dependent Resistance to adriamycin in human lukemia cell line K562/A02]. Ai Zheng. 2008 May;27(5):491-5. Chinese. PubMed PMID: 18479598. 18: Xiao SH, Wei GL, Lu R, Liu CX, Wang FP. [Tissue distribution and excretion of bromotetrandrine in rats]. Yao Xue Xue Bao. 2005 May;40(5):453-6. Chinese. PubMed PMID: 16220792. 19: Jin J, Wang FP, Wei H, Liu G. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Cancer Chemother Pharmacol. 2005 Feb;55(2):179-88. PubMed PMID: 15378274. 20: Ren Y, Zhang H, Chen B, Cheng J, Cai X, Liu R, Xia G, Wu W, Wang S, Ding J, Gao C, Wang J, Bao W, Wang L, Tian L, Song H, Wang X. Multifunctional magnetic Fe3O4 nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance. Int J Nanomedicine. 2012;7:2261-9. doi: 10.2147/IJN.S29357. PubMed PMID: 22619560; PubMed Central PMCID: PMC3356215.